FIG. 1

InterMune, Inc.
Protocol GIPF-001: Subcutaneous IFN-γ for Idiopathic Pulmonary Fibrosis

Table 19.3.3

Cumulative Probability of Survival^ - Kaplan-Meier Estimates (Standard Errors)
Baseline FVC % Predicted: < 55
Intent-to-Treat

Week	IFN-γ 1b (N = 36)	Placebo (N = 40)	P-Value*
Week 12	0.92 (0.046)	0.98 (0.025)	
Week 24	0.89 (0.052)	0.90 (0.047)	
Week 36	0.83 (0.062)	0.88 (0.052)	
Week 48	0.75 (0.073)	0.82 (0.061)	
Week 60	0.75 (0.073)	0.82 (0.061)	
Week 72	0.68 (0.090)	0.82 (0.061)	
Week 84	0.68 (0.090)	0.82 (0.061)	0.434
Time to Survival (Days)# 75th Percentile	318.0	-	
Number (%) of Survivors	26 (72.2%)	33 (82.5%)	

^ Distribution of time to the occurrence of death.
# Time to Survival (Days) = Date of death - Date of randomization +1.
For patients who survive as of 6/26/2002 the time to survival was considered a censored observation.
Days = June 26 2002 - Date of randomization +1.
* Test for treatment effect using log rank test stratified by smoking status.

WO 2004/019758
PCT/US2003/026388

FIG.2

InterMune, Inc.
Protocol GIPF-001: Subcutaneous IFN-γ for Idiopathic Pulmonary Fibrosis

Table 19.3.6

Cumulative Probability of Survival^ - Kaplan-Meier Estimates (Standard Errors)
Baseline FVC % Predicted: ≥ 55
Intent-to-Treat

Week	IFN-γ 1b (N = 126)	Placebo (N = 128)	P-Value*
Week 12	1.00 (0.000)	0.99 (0.008)	
Week 24	0.98 (0.011)	0.98 (0.011)	
Week 36	0.98 (0.011)	0.94 (0.021)	
Week 48	0.98 (0.014)	0.90 (0.026)	
Week 60	0.94 (0.027)	0.85 (0.034)	
Week 72	0.94 (0.027)	0.80 (0.047)	
Week 84	0.94 (0.027)	0.68 (0.090)	0.004
Time to Survival (Days)# 75th Percentile	-	518.0	
Number (%) of Survivors	120 (95.2%)	107 (83.6%)	

^ Distribution of time to the occurrence of death.
# Time to Survival (Days) = Date of death - Date of randomization +1.
For patients who survive as of 6/26/2002 the time to survival was considered a censored observation.
Days = June 26 2002 - Date of randomization +1.
* Test for treatment effect using log rank test stratified by smoking status.

WO 2004/019758
2/2
PCT/US2003/026388
10/525583